Cortex Pharmaceuticals, Inc. Enters Into New License Agreement With the University of Illinois Granting Cortex Patent Rights to the Use of Cannabinoids for the Treatment of Sleep Related Breathing Disorders
Cortex Announces Positive Phase 2 Data for Use of Dronabinol in the Treatment of Obstructive Sleep Apnea GLEN ROCK, N.J., July 1, 2014 (GLOBE NEWSWIRE) — Cortex Pharmaceuticals, Inc. (CORX) (“Cortex” or the “Company”), a biopharmaceutical company currently engaged in the development of drugs for respiratory disorders, announced today that it has entered into a…